±
Boost – EORTC Trial
Bartelink H, Lancet Oncol 2015; 16:47-56
Follow up: 20y
N = 4.318
Age
Gain (LR)
≤40
11.6%
41-50
5.9%
51-60
2.9%
>60
3%
≤40a
41-50a
51-60a
>60a